NorthSea Therapeutics
NorthSea Therapeutics was founded in 2017 by a group of experienced biotech entrepreneurs and scientists with a track record of success in developing and commercializing innovative therapies for metabolic and liver diseases. The company has raised over $200 million in funding from leading life science investors, including Forbion, Novo Holdings, venBio Partners, Sofinnova Investments, and New Science Ventures. NorthSea Therapeutics reported revenue of $5M for FY 2022.
The lead product candidate of NorthSea Therapeutics is icosabutate, a once-daily, oral SEFA that is currently in a Phase 2b clinical trial for the treatment of NASH, a chronic liver disease that affects millions of people worldwide, and has no approved therapies. NASH is characterized by fat accumulation, inflammation, and fibrosis in the liver, which can lead to cirrhosis, liver failure, and liver cancer. Icosabutate has shown promising results in a pre-specified interim analysis of Phase 2b trial, demonstrating significant improvements in liver function parameters, inflammatory and fibrotic biomarkers, lipid profile, and glycemic control. Icosabutate has also been well-tolerated, with no serious safety signals to date. The final data from the Phase 2b trial are expected in Q1 2023.
NorthSea Therapeutics has received several awards and recognitions for its innovative approach and achievements. In 2019, the company won the BioCapital Europe Award for Best Company Presentation. In 2020, the company was selected as one of the Fierce 15 Biotech Companies of the Year by Fierce Biotech. In 2021, the company was named as one of the Top 20 Biotech Startups to Watch by Labiotech.eu.
Foundation: 2017
Headquarters: Naarden, Noord-Holland, The Netherlands.
Website: https://www.northseatherapeutics.com/
